We have found that repeated anti-CD137 treated lupus prone NZB/W F1 mice develop multi-focal hepatitis. Cessation of anti-CD137 treatment led to the resolution of hepatitis. To determine whether development of hepatitis was or was not related to the susceptibility of NZB/W F1 mice to autoimmune disease, we repeatedly injected normal naive mice with therapeutic doses of anti-CD137. Like NZB/W F1 mice, we found that normal mice also developed hepatitis. Further
Ctrl 2 5
Was this article helpful?